Literature DB >> 28686970

Endocytic pathways of optimized resveratrol cubosomes capturing into human hepatoma cells.

Hend Mohamed Abdel-Bar1, Rania Abd El Basset Sanad2.   

Abstract

Resveratrol (RSV) is a natural polyphenolic compound with high affinity to hepatocytes. It has numerous benefits as anticancer, antioxidant, immunomodulatory and cardioprotective actions. Nevertheless, RSV therapeutic applications are hindered by its low solubility, light sensitivity and extensive first-pass metabolism. Cubosomes are colloidally stable dispersed liquid crystalline nanoparticles. The incorporation of RSV into cubosomes could overcome some of its physicochemical limitations. A Design-Expert® software was applied to optimize cubosomes in terms of particle size and encapsulation efficiency (EE%). The used model proved its suitability in predicting optimum cubosomal size. The prepared cubosomes showed an enhanced HepG2 cytotoxicity except at particle size of ≈20nm. Different endocytic pathways mechanisms as macropinocytosis, clathrin-mediated endocytosis and caveolae-mediated endocytosis were identified in the cellular uptake of RSV cubosomes depending on particle size. Caveolae-mediated transport was shown to have a significant effect on RSV cubosomes internalization efficiency and cytotoxicity.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Caveolae; Cubosomes; Cytotoxicity; Endocytic pathways; Resveratrol

Mesh:

Substances:

Year:  2017        PMID: 28686970     DOI: 10.1016/j.biopha.2017.06.093

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  Liquid Crystalline Phases for Enhancement of Oral Bioavailability.

Authors:  Xingwang Zhang; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2021-02-22       Impact factor: 3.246

2.  Prunus armeniaca Gum-Alginate Polymeric Microspheres to Enhance the Bioavailability of Tramadol Hydrochloride: Formulation and Evaluation.

Authors:  Shazia Noureen; Sobia Noreen; Shazia Akram Ghumman; Fozia Batool; Huma Hameed; Sara Hasan; Fozia Noreen; Mervat A Elsherif; Syed Nasir Abbas Bukhari
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

3.  Comprehensive and comparative studies on nanocytotoxicity of glyceryl monooleate- and phytantriol-based lipid liquid crystalline nanoparticles.

Authors:  Jakub Jagielski; Łucja Przysiecka; Dorota Flak; Magdalena Diak; Zuzanna Pietralik-Molińska; Maciej Kozak; Stefan Jurga; Grzegorz Nowaczyk
Journal:  J Nanobiotechnology       Date:  2021-06-03       Impact factor: 10.435

4.  An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect.

Authors:  Mohamed Hamdi; Hend Mohamed Abdel-Bar; Enas Elmowafy; Khuloud T Al-Jamal; Gehanne A S Awad
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

5.  Lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies.

Authors:  Hend Mohamed Abdel-Bar; Inas A Abdallah; Marwa A A Fayed; Yassmin Moatasim; Ahmed Mostafa; Mohammed Farrag El-Behairy; Hanan Elimam; Yaseen A M M Elshaier; Khaled A M Abouzid
Journal:  RSC Adv       Date:  2021-08-27       Impact factor: 4.036

6.  Niosomal Nanocarriers for Enhanced Dermal Delivery of Epigallocatechin Gallate for Protection against Oxidative Stress of the Skin.

Authors:  Danhui Li; Nataly Martini; Zimei Wu; Shuo Chen; James Robert Falconer; Michelle Locke; Zhiwen Zhang; Jingyuan Wen
Journal:  Pharmaceutics       Date:  2022-03-28       Impact factor: 6.525

7.  AT101-Loaded Cubosomes as an Alternative for Improved Glioblastoma Therapy.

Authors:  Dorota K Flak; Vivian Adamski; Grzegorz Nowaczyk; Kosma Szutkowski; Michael Synowitz; Stefan Jurga; Janka Held-Feindt
Journal:  Int J Nanomedicine       Date:  2020-10-05

Review 8.  Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review.

Authors:  Yosif Almoshari
Journal:  Pharmaceutics       Date:  2022-03-09       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.